Kraig Biocraft Laboratories In Stock Price, News & Analysis

Kraig Biocraft Laboratories (OTCQB: KBLB) promoted Dr. Xiaoli Zhang to Chief Scientist on October 27, 2025 after leading a series of scientific breakthroughs in spider silk-based super materials. Dr. Zhang joined Kraig Labs in October 2024 and, according to the company, accelerated the research program to exceed milestones and advance next-generation fiber and bioengineered materials.

The announcement highlights breakthroughs in spider silk production at the company's operations centers in Southeast Asia and frames the promotion as part of Kraig Labs' push to commercialize sustainable, higher-margin performance materials.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced the start of its sixth 2025 spider silk production cycle on October 20, 2025, introducing the first large-scale deployment of its BAM-1 Alpha recombinant spider silk hybrid.

The company says BAM-1 Alpha builds on 2024 breakthroughs to deliver stronger performance and higher silk yields while fitting existing production schedules and infrastructure. The cycle scales parental lines and continues use of diapause egg management to improve efficiency, logistics, and sustained throughput across cycles.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced a selective breeding advancement that materially increases recombinant spider silk production throughput. By mating an improved parental strain with a BAM-1 parent, the Company created the BAM-1 Alpha hybrid, which demonstrated 22% higher cocoon shell weight (the company's measure of silk output) and an increase in hybrid vigor of more than 245% versus the original BAM-1. BAM-1 Alpha will be deployed across Kraig's multi-facility production infrastructure to support commercial manufacturing and lower per-unit production cost, while robustness data beyond shell weight remains unquantified.

Kraig Biocraft Laboratories (OTCQB: KBLB) announced plans to add a third recombinant spider silk rearing center as part of a rapid production expansion. The company said it has opened two centers over the past 18 months and is identifying a site for the third facility, expecting to finalize a location within 60 days from the Oct. 6, 2025 announcement. The new center will be located in a leading silk‑production region to leverage local sericulture expertise, and the multi‑facility strategy is intended to enable continuous production and operational redundancy.

Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has achieved a significant operational milestone by successfully completing its first simultaneous production cycle across two independent rearing centers. The company implemented a strategic two-week offset between facility start times, enabling continuous production of cocoons and silkworm eggs while eliminating downtime between cycles.

This dual-facility model demonstrates Kraig Labs' ability to manage parallel operations with independent teams while maintaining quality standards. The achievement validates their scalable production model and sets the foundation for planned fourth-quarter production expansion. The synchronized operations enhance supply chain resilience and increase throughput capacity, positioning the company to meet growing market demand for recombinant spider silk.

Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced plans to acquire an additional silkworm rearing center as part of its multi-facility expansion strategy. This expansion follows 18 months of significant production growth under Dr. Nirmal Kumar's expertise, after relocating its operating headquarters to Asia's traditional silk-producing regions.

The company has achieved record production volumes and established a scalable foundation for recombinant spider silk manufacturing. The planned facility expansion aims to create a production network for continuous rearing cycles, enhanced reliability, and increased capacity to meet growing global demand across industries including textiles, apparel, defense, and consumer goods.

Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has appointed Kenneth Le as Managing Director of its wholly-owned subsidiary, Prodigy Silk Ltd. Le, who has been instrumental in the company's Southeast Asian operations, will oversee the expansion of spider silk rearing and production systems.

Under Le's previous leadership, Kraig Labs and Prodigy Silk have evolved from pilot-scale operations to full-scale commercial rearing centers. In his new role, Le will focus on accelerating production, expanding capacity, and strengthening integration with production partners to advance the commercialization of recombinant spider silk technology.

Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, announced that Dr. Nirmal Kumar, their lead sericulture expert, has joined the production team at their new Southeast Asian rearing facility.

Dr. Kumar will oversee the first production cycle at the new center, focusing on BAM-1 spider silk production. His responsibilities include supervising the development of an expanded BAM-1 egg production center and testing lab. The company is also exploring partnerships with secondary processing providers and is in discussions with a potential customer regarding a custom spider silk thread order.

This development marks a significant step in Kraig Labs' transition to continuous production of their first recombinant spider silk hybrid line, positioning the company to meet growing market demand.

Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced the successful transition of its production operations to two new rearing centers in a major Southeast Asian silk-producing region. The new facilities, operated by the Company's subsidiary Prodigy Silk, have already surpassed all previous years of production combined since the first center opened in early 2024.

The modern rearing centers combine advanced biotechnology with the region's established sericulture expertise, favorable climate, and infrastructure. The Company is completing the transfer of equipment from its original pilot facility, with completion expected by the end of August 2025. This strategic move represents a significant expansion milestone for Kraig Labs in commercializing spider silk technology.